LMOFX Mutual Fund

LMOFX Mutual Fund

NAV$58.08
See how much of LMOFX you already own
Just $25 once·$69/mo·Download sample
X-ray my portfolio free

Fund Essentials - as of Mar 31, 2026

Net Assets
$11M
Expense Ratio
1.74%
Dividend Yield (Current)
-
Holdings
36
Inception Date
Feb 13, 2004
Fund Family
Patient Capital Management
Investment Style
PRO
Asset Class
PRO
Legal Structure
PRO
Dividend Frequency
Annually

Performance

YTD+12.37%
1 Year+29.57%
3 Year+22.97%
5 Year+6.35%
10 Year+13.98%

Asset Allocation

Stocks: 94.30%
Other: 5.70%
See how much of LMOFX you already own
Your funds unpacked, overlap, fees and score, free on screen. The full report is $25, once. Download sample.
X-ray my portfolio free

Top Holdings

View All →
TickerNameWeight
RPD:DURoyalty Pharma Plc Class A Ordinary Share6.91%
CCitigroup Inc.6.54%
GOOGAlphabet Inc. C6.30%
QXOQxo, Inc.5.60%
AMZNAmazon.Com Inc5.46%
Top 10 Concentration: 53.42%Report Date: Mar 31, 2026
Download all 36 holdings for LMOFX
CSV export with sector, industry & share changes
Get CSV

Dividend Summary

View Details →
Frequency
Annually
Latest Distribution
$0.45
-

Peer Comparison

Benchmark
PRO
Peer outperformance: PRO
Category rank: PRO
This Mutual Fund
PRO
Peer Avg
PRO

LMOFX Mutual Fund Overview

LMOFX Mutual Fund (Patient Opportunity Trust Class FI) is managed by Patient Capital Management with $11.2M in net assets. LMOFX expense ratio is 1.74%, holding 36 positions across sectors including Financials, Consumer Discretionary, Health Care. Inception date: 2004-02-13.

LMOFX performance shows a YTD return of 12.37%. The 1-year return is 29.57% and the 5-year return is 6.35%.

LMOFX top holdings include Royalty Pharma Plc Class A Ordinary Share (6.9%), Citigroup Inc. (6.5%), Alphabet Inc. C (6.3%), Qxo, Inc. (5.6%), Amazon.Com Inc (5.5%). Go to all LMOFX holdings, LMOFX sectors, or LMOFX dividends.

LMOFX can be compared against other funds. Use LMOFX overlap to find shared positions, or LMOFX vs another fund for a side-by-side view. LMOFX alternatives are available via the screener, along with tax-loss harvesting opportunities.